Impact of Growth Hormone on Scoliosis in Children

Growth Hormone and Its Role in Pediatric Scoliosis

Growth hormone (GH) plays a critical role in growth and development, particularly in children. It is secreted by the pituitary gland and stimulates growth in various tissues, including bone and cartilage. The physiological effects of GH are mediated through insulin-like growth factor 1 (IGF-1), which is produced in response to GH stimulation. Recent studies have suggested that alterations in GH levels may influence the development and progression of scoliosis, specifically adolescent idiopathic scoliosis (AIS), which affects 2% to 5.2% of children and adolescents (Zhang et al., 2023).

Scoliosis is characterized by a three-dimensional deformity of the spine, primarily manifested as a lateral curvature and associated with vertebral rotation. The etiology of scoliosis is multifactorial, involving genetic predispositions, hormonal influences, and environmental factors. The relationship between GH and scoliosis has garnered interest due to evidence indicating that GH therapy could potentially exacerbate or mitigate scoliosis progression, depending on the individual patient characteristics (Zhang et al., 2023).

Prevalence and Types of Scoliosis in Children

Scoliosis in children can be categorized into several types based on its etiology. The most common type is adolescent idiopathic scoliosis (AIS), typically diagnosed during the growth spurts of adolescence. Other types include congenital scoliosis, neuromuscular scoliosis, and syndromic scoliosis. According to studies, the prevalence of scoliosis ranges between 2% to 5.2% in children, with a notable increase during periods of rapid growth (Zhang et al., 2023).

Table 1: Types of Scoliosis and Their Characteristics

The clinical manifestations of scoliosis can include visible deformities such as shoulder asymmetry, uneven waist, and changes in posture. Early detection is crucial for effective management, as the degree of curvature may progress significantly during growth periods, leading to complications such as chronic pain and respiratory issues.

Mechanisms Behind Hormonal Influence on Scoliosis Progression

The mechanisms through which GH and other hormones influence scoliosis remain an area of active research. Current theories suggest that hormonal imbalances affecting bone metabolism may contribute to the development and progression of scoliosis. For instance, changes in sex hormones, such as estrogen and testosterone, during puberty may exacerbate spinal deformities in susceptible individuals (Zhang et al., 2023).

Bone density and growth velocity are closely linked to GH levels. Studies have indicated that children with scoliosis often exhibit altered bone density and morphology, which can be influenced by GH treatment. The GH/IGF-1 axis is critical for bone growth, as GH stimulates the growth plate chondrocytes, promoting linear bone growth and influencing the structure of the vertebrae (Zhang et al., 2023).

Table 2: Hormonal Factors Affecting Scoliosis

The understanding of these hormonal interactions is crucial in developing therapeutic strategies for managing scoliosis in children, particularly those receiving GH therapy for growth deficiencies.

Recombinant Human Growth Hormone: Efficacy and Risks

Recombinant human growth hormone (rhGH) therapy has been utilized to treat various growth disorders, including idiopathic short stature and growth hormone deficiency. While rhGH therapy is effective in promoting growth and improving height standard deviation scores (SDS), concerns regarding its potential role in scoliosis progression persist (Zhang et al., 2023).

Recent studies have shown that children treated with rhGH may experience an increased risk of scoliosis development or progression. For example, a multicenter study indicated that 4% of children on GH therapy developed scoliosis, compared to a lower prevalence in the general population (Zhang et al., 2023). The influence of rhGH on spinal growth dynamics and bone density is thought to be a contributing factor.

Risks Associated with rhGH Therapy

1. Increased Incidence of Scoliosis: Children with pre-existing conditions such as Turner syndrome or Prader-Willi syndrome may be at a higher risk for scoliosis progression when treated with rhGH.
2. Altered Bone Density: Changes in bone mineralization can lead to a higher likelihood of skeletal deformities, including scoliosis.
3. Need for Monitoring: Regular assessments of spinal curvature in patients receiving rhGH therapy are recommended to detect any changes early.

Table 3: Efficacy and Risks of rhGH Therapy

Future research should focus on elucidating the long-term effects of rhGH on spinal health, particularly in populations predisposed to scoliosis.

Future Research Directions on Growth Hormone and Scoliosis

The existing literature highlights a need for further investigation into the relationship between growth hormone therapy and scoliosis. Future research should aim to:

1. Establish Longitudinal Studies: Long-term follow-up studies on children receiving rhGH can provide insights into the risks of scoliosis and the effectiveness of interventions.
2. Explore Mechanisms: Investigating the biological mechanisms through which GH affects spinal curvature can help refine therapeutic approaches.
3. Develop Risk Stratification Models: Identifying risk factors for scoliosis in children receiving GH therapy can guide clinical decision-making and monitoring strategies.

Table 4: Future Research Areas

Understanding these aspects will be crucial in optimizing treatment strategies for children with growth disorders and scoliosis.

Frequently Asked Questions (FAQ)

What is scoliosis?

Scoliosis is a three-dimensional curvature of the spine that can lead to various physical complications and discomfort. It is most commonly diagnosed in adolescents.

How does growth hormone affect scoliosis?

Growth hormone may influence the growth and development of bones, and in some cases, it can exacerbate the progression of scoliosis.

What are the treatment options for scoliosis?

Treatment options may include observation, bracing, and surgical intervention depending on the severity of the curvature and the age of the patient.

Is rhGH safe for children with scoliosis?

While rhGH can promote growth, its effects on scoliosis progression necessitate careful monitoring and assessment by healthcare providers.

How can scoliosis be monitored?

Regular physical examinations and imaging studies, such as X-rays, are necessary for monitoring the progression of scoliosis in affected individuals.

References

1. Zhang, X.-K., Li, X., Shi, M.-Y., et al. (2023). Impact of growth hormone on scoliosis. Pediatr Discov, 1(3), e26
2. Cheng, J. C. Y., Castelein, R. M., Chu, W. C. W., et al. (2015). Adolescent idiopathic scoliosis. Nat Rev Dis Primers, 1, 15030. https://doi.org/10.1038/nrdp.2015.30
3. Altaf, F., Gibson, A., Dannawi, Z., Noordeen, H. (2013). Adolescent idiopathic scoliosis. BMJ, 346. https://doi.org/10.1136/bmj.f2508
4. Scherl, S. A. (2022). Adolescent idiopathic scoliosis: clinical features, evaluation, and diagnosis. UpToDate.
5. Dimeglio, A., & Canavese, F. (2013). Progression or not progression? How to deal with adolescent idiopathic scoliosis during puberty. J Child Orthop, 7(1), 43-49
6. Negrini, S., Donzelli, S., Aulisa, A. G., et al. (2018). 2016 SOSORT guidelines: orthopaedic and rehabilitation treatment of idiopathic scoliosis during growth. Scoliosis Spinal Disord, 13(1), 3. https://doi.org/10.1186/s13013-017-0145-8
7. Cheng, J. C., Tang, S. P., Guo, X., Chan, C. W., Qin, L. (2001). Osteopenia in adolescent idiopathic scoliosis: a histomorphometric study. Spine, 26(3), E19-E23
8. Wang, E. D., Drummond, D. S., Dormans, J. P., Moshang, T., Davidson, R. S., Gruccio, D. (1997). Scoliosis in patients treated with growth hormone. J Pediatr Orthop, 17(6), 708-711
9. Ranke, M. B., & Wit, J. M. (2018). Growth hormone - past, present and future. Nat Rev Endocrinol, 14(5), 285-300
10. Kim, J. Y., Rosenfeld, S. R., Keyak, J. H. (2001). Increased prevalence of scoliosis in Turner syndrome. J Pediatr Orthop, 21(6), 765-766
11. Cheung, J. P. Y., Cheung, P. W. H., Samartzis, D., Luk, K. D. K. (2018). Curve progression in adolescent idiopathic scoliosis does not match skeletal growth. Clin Orthop Relat Res, 476(2), 429-436
12. Suh, S. W., Modi, H. N., Yang, J. H., Hong, J. Y. (2011). Idiopathic scoliosis in Korean schoolchildren: a prospective screening study of over 1 million children. Eur Spine J, 20(7), 1087-1094
13. Trobisch, P., Suess, O., Schwab, F. (2010). Idiopathic scoliosis. Dtsch Arztebl Int, 107(49), 875-884. https://doi.org/10.3238/arztebl.2010.0875
14. Daughaday, W. H. (2006). Endocrinology—the way we were: a personal history of somatomedin. Growth Horm IGF Res, 16(Suppl A), S3-S5. https://doi.org/10.1016/j.ghir.2006.03.005
15. Tritos, N. A., & Klibanski, A. (2016). Effects of growth hormone on bone. Prog Mol Biol Transl Sci, 138, 193-211. https://doi.org/10.1016/bs.pmbts.2015.10.008
16. Liang, Z. T., Guo, C. F., Li, J., Zhang, H. Q. (2021). The role of endocrine hormones in the pathogenesis of adolescent idiopathic scoliosis. FASEB J, 35(9), e21839
17. Clark, P. A., & Rogol, A. D. (1996). Growth hormones and sex steroid interactions at puberty. Endocrinol Metab Clin N Am, 25(3), 665-681 05)70346-7
18. Alharbi, M. S. (2022). Growth hormone therapy in short-stature patients with kyphoscoliosis: a literature review. EFORT Open Rev, 7(3), 240-246
19. Ranke, M. B. (1996). Towards a consensus on the definition of idiopathic short stature. Horm Res, 45(Suppl 2), 64-66
20. Cohen, P., Rogol, A. D., Deal, C. L., et al. (2008). Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab, 93(11), 4210-4217
21. Child, C. J., Quigley, C. A., Cutler, G. B. (2019). Height gain and safety outcomes in growth hormone-treated children with idiopathic short stature: experience from a prospective observational study. Horm Res Paediatr, 91(4), 241-251
22. Park, S. J., Lee, K. H., Lee, C. S., et al. (2020). Impact of growth hormone treatment on scoliosis development and progression: analysis of 1128 patients with idiopathic short stature. J Pediatr Endocrinol Metab, 34(2), 243-250
23. Cheung, C. S., Lee, W. T., Tse, Y. K., et al. (2006). Generalized osteopenia in adolescent idiopathic scoliosis—association with abnormal pubertal growth, bone turnover, and calcium intake? Spine, 31(3), 330-338
24. Cheng, J. C. Y., Qin, L., Cheung, C. S., et al. (2000). Generalized low areal and volumetric bone mineral density in adolescent idiopathic scoliosis. J Bone Min Res, 15(8), 1587-1595
25. Ranke, M. B., & Wit, J. M. (2018). Growth hormone—past, present and future. Nat Rev Endocrinol, 14(5), 285-300